Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Sponsors » Next-Generation Discovery Workflows » Epigenome Study Maps Hydroxymethylation Across Diverse Human Tissue Types

Epigenome Study Maps Hydroxymethylation Across Diverse Human Tissue Types

Dec 02, 2020
|
staff reporter

NEW YORK – Researchers at the University of Chicago, Bluestar Genomics, and elsewhere have developed a genome-wide tissue map of the DNA 5-hydroxymethylcytosine (5hmC) modification that revealed its role in tissue-specific development and as a potential diagnostic and prognostic biomarker for a variety of human diseases.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Quick Changes If Needed

Moderna says it would be able to quickly update its SARS-CoV-2 vaccine to address new genetic variants if needed, MIT's Technology Review reports.

Early Results on Johnson & Johnson's SARS-CoV-2 Vaccine

Johnson & Johnson reports interim results from a Phase 1/2 study of its SARS-CoV-2 vaccine in the New England Journal of Medicine, according to Bloomberg.

WHO Team Arrives

Investigators from the World Health Organization have arrived in China to look into the origins of SARS-CoV-2, NPR reports.

Nature Papers Present Amplicon Sequencing Approach, Dire Wolf Genomes

In Nature this week: a new method for high-throughput amplicon sequencing, and more.

Feb
18
Featured Webinar

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
25
Featured Webinar

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.